Publications by authors named "J P Castaigne"
Article Synopsis
- Axi-cel (axi-cel) and tisagenlecleucel (tisa-cel) are advanced T-cell therapies for treating resistant diffuse large B-cell lymphoma (DLBCL), evaluated in major clinical trials (ZUMA-1 and JULIET) and a French registry that examined data from 729 patients.
- Axi-cel showed better overall survival and progression-free survival compared to tisa-cel but was linked to more severe immune-related side effects, while no significant difference was found in serious cytokine release syndrome.
- The cost-effectiveness analysis indicated that axi-cel is more economically favorable, costing €15,520 per quality-adjusted life year compared to tisa-cel.
To quantify the clinical unmet need of r/r MCL patients who progress on a covalent Bruton tyrosine kinase inhibitor (BTKi), we conducted a systematic review to identify studies that reported overall survival (OS), progression-free survival (PFS), or response outcomes of patients who received a chemo(immunotherapy) ± targeted agent standard therapy (STx) or brexucabtagene autoleucel (brexu-cel) in the post-BTKi setting. Twenty-six studies (23 observational; three trials) reporting outcomes from 2005 to 2022 were included. Using two-stage frequentist meta-analyses, the estimated median PFS/OS for patients treated with an STx was 7.
View Article and Find Full Text PDFBrexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 CAR T-cell therapy approved in the USA and European Union (EU) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL; aged ≥26 years in EU). Here, outcomes for patients with R/R B-ALL aged ≥26 years in ZUMA-3 treated with brexu-cel were compared with historical standard-of-care (SOC) therapy. After median follow-up of 26.
View Article and Find Full Text PDFThe present review details the recommendations for the management of acute pyelonephritis in adults. Acute pyelonephritis corresponds to the infection of the upper urinary tract and is particularly common in women between the age of 15 and 65 years. Symptoms usually include fever, chills, flank pain, nausea and vomiting.
View Article and Find Full Text PDFIntroduction: Despite currently available treatments for adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL), survival outcomes remain poor, highlighting the need for new therapeutic strategies. This study estimates the cost-effectiveness of KTE-X19 to treat adults with R/R ALL from a US payer perspective.
Methods: The model had two components: a decision-tree, where pre-infusion costs for patients who ultimately did not receive KTE-X19 are accounted for, followed by a partitioned survival analysis, where all KTE-X19 infused patients would enter the three-state (pre-progression, progressed disease, death) model.